Molnupiravir for the treatment of non-severe COVID-19: a systematic review and meta-analysis of 14 randomized trials with 34 570 patients–authors’ response

Sun, Mingyao; Lai, Honghao; Zhang, Zhigang; Ge, Long

doi:10.1093/jac/dkad336

Journal of Antimicrobial Chemotherapy

2023

DOI: 10.1093/jac/dkad336

|View full text |Cite

Molnupiravir for the treatment of non-severe COVID-19: a systematic review and meta-analysis of 14 randomized trials with 34 570 patients–authors’ response

Mingyao Sun,

Honghao Lai,

Zhigang Zhang

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

The emergence and implications of SARS-CoV-2 omicron subvariant BA.2.86 on global health

Satapathy,

Kumar,

Gupta

et al. 2024

International Journal of Surgery

View full text Add to dashboard Cite

The SARS-CoV-2 subvariant BA.2.86 “Pirola”, first identified in Denmark in August 2023, has manifested with a significantly mutated spike protein profile, suggesting a heightened ability to evade vaccine- and infection-induced antibodies. This article outlines the epidemiological spread, immune response implications, and global responses to BA.2.86. Preliminary observations indicate community transmissions of the subvariant, even among those previously infected or vaccinated. Notably, the BA.2.86 infection has shown potential to amplify antibody responses. The variant’s emergence has evoked memories of the Omicron variant’s rise in late 2021, though global immunity levels might modulate BA.2.86’s impact differently. Continuous genomic surveillance, coupled with integrated diagnostic and epidemiological strategies, proves crucial in early detection and management. The emergence of BA.2.86 reaffirms the unpredictable nature of the COVID-19 pandemic, emphasizing the need for ongoing research, adaptability, and global collaboration.

show abstract

The emergence and implications of SARS-CoV-2 omicron subvariant BA.2.86 on global health

Satapathy,

Kumar,

Gupta

et al. 2024

International Journal of Surgery

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Molnupiravir for the treatment of non-severe COVID-19: a systematic review and meta-analysis of 14 randomized trials with 34 570 patients–authors’ response

Cited by 1 publication

References 7 publications

The emergence and implications of SARS-CoV-2 omicron subvariant BA.2.86 on global health

The emergence and implications of SARS-CoV-2 omicron subvariant BA.2.86 on global health

Contact Info

Product

Resources

About